FDA OK's Impax's long-awaited Parkinson's drug Rytary
The FDA on 8 January finally gave its blessing to Impax Pharmaceuticals to market its Parkinson's disease drug Rytary, an extended-release oral capsule formulation of carbidopa-levodopa.
The FDA on 8 January finally gave its blessing to Impax Pharmaceuticals to market its Parkinson's disease drug Rytary, an extended-release oral capsule formulation of carbidopa-levodopa.